Petros Pharmaceuticals gibt Ergebnisse der Aktionärsversammlung involved with Investing.com

On 20.11.2024, Petros Pharmaceuticals, Inc., a Delaware pharmaceutical company, ceased its annual action. It may be that you have more to do with the abolition of the Vorschläge, while you can use the Wiederwahl of the Vorstandsmitgliedern, the Bestätigung des Wirtschaftsprüfers, the Vergütung der Führungskräfte und een mögliche Aktienzusammenlegung.

The actions were carried out by Joshua N. Silverman, Bruce T. Bernstein and Wayne R. Walker in the Vorstand. Your Amtszeit-läuft is to the New Year in 2025 or to his Wahl in the next phase. The Zustimmung for the Directors was 1,897,502 and 1,900,520 Stimmen.

With 3,984,099 Ja-Stimmen, Marcum LLP wurde as one of the best Wirtschaftsprüfers for the Geschäftsjahr 2024. The Vergütung der Führungskräfte is in een Konsultativabstimmung 1,433,687 Ja-Stimmen.

A bedeutnder-beschluss-war wich is the generation of a subdivision of the unternehmenssatzung, is an action in the display of 1:2 to 1:25 ermöglicht. Der Vorstand may come to an end in the inner part of the following years. Dieser Vorschlag erhielt 2,949,518 Ja-Stimmen.

The Abstimmungsergebnisse is based on the US Securities and Exchange Commission and filed a Stimmrechtsvollmacht on 25.10.2024, on 18.11.2024. The Aktien von Petros Pharmaceuticals became a Nasdaq company under the Kürzel PTPI trading.

In another article, Petros Pharmaceuticals said that the Grundgehalt of Fady Boctor, its Chairman and Chief Commercial Officer, earned US$350,000 to US$280,000 per year. If there are other people who are engaged in washing food, make sure that this is not the case with their appearance at Petros cold animals.

If the independence of the series A walking bars was earlier, the previous action was more of an influence on external human separation. The research of Petros Pharmaceuticals has led to the fact that the drug has an erectile dysfunction, STENDRA, which results in rezeptfreien Status zu überführen. Research into STENDRA’s proprietary app technology has yielded a number of positive results in the Selbstauswahl by patients.

Zwei Vorstandsmitglieder, John Shulman and Greg Bradley, who have done their work, have no experience whatsoever in conveying an onternehmensabläufe. Zudem is a Petros Partnership with the Telemedicine Provider Lemonaid Health eingedingen, a knowledge base in its area.

InvestingPro Insights

Petros Pharmaceuticals’ young people’s separations, which promote cooperation with the companies, mirror the active financial herausforderungen more broadly. Laut InvestingPro-Daten have bet the market capitalization of the Unternehmens completely 2.5 million US dollars. InvestingPro tips give you the impression that Petros has “schnell Bargeld verrennt” and the “kurzfristigen Verpflichtungen die liquiden Mittel übersteigen”.

If the economy is worth $4.02 million in the final months of the third quarter of 2024, there will be a 42.41% saving in the history of the war. Another InvestingPro Tipp said he said “analysts are no longer active, but the companies are profitable in those years.”

For part of InvestingPro 11’s analysis, along with a stake in Petros Pharmaceuticals, investors are a financial view of low and market performance of our third-party companies.

This description can be performed by the intelligent intelligence. Weitere Informationen entnehmen Sie bitte unseren Nutzungsbedingungen.